#SFHS2609224AOrder Adding BAHA 7 Processor to Reimbursable Products
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law officially adds the BAHA 7 processor for bone-anchored hearing aids to the list of reimbursable healthcare products in France. The BAHA 7 system is designed for patients with specific hearing loss conditions where traditional hearing aids are ineffective. The law outlines its components, indications for use, and requirements for prescription by trained healthcare professionals.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of BAHA 7 processor under reimbursable products
- Specifications on prescription by trained multidisciplinary teams
- Indications for coverage specified for certain types of hearing loss
Obligations
What this law requires
Add BAHA 7 processor (code 2384447) to the reimbursable healthcare products list under Cochlear France SAS in Title II, Chapter 3, Section 7
Prescribe and implant BAHA 7 only through a multidisciplinary team that has received specific training for implantation, including at least one ORL (ear, nose, throat specialist) and one hearing aid professional
Conduct a pre-implantation clinical and audiometric assessment for all patients
Perform a standardized trial period of approximately 3 weeks with hearing aid solutions (air and bone conduction) prior to implantation when possible
Conduct post-trial objective and subjective benefit evaluation including tonal and vocal audiometry in silence and noise, quality of life questionnaire, and stereoaudiometry where applicable